SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending following a strong quarterly earnings report featuring revenue growth that beat analyst expectations and raised full-year guidance, fueled by accelerating enterprise adoption of its AI-powered features. Community sentiment is heavily focused on a potential short squeeze, with investors highlighting significant short interest and arguing that the companys strong net dollar retention and essential role in design workflows prove its long-term value despite broader market concerns about AI competition.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is seeing heightened community discussion as traders weigh the impact of potential domestic production delays against significant long-term institutional interest and government support for critical mineral independence. Investors are actively dissecting recent quarterly operational results while speculating on the significance of upcoming federal grant opportunities and the company's role in the domestic supply chain for critical defense materials.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending as investors digest a strong earnings beat and bullish forward guidance, which the community sees as a clear proxy for the ongoing AI-driven semiconductor supercycle. While bulls are celebrating the company's ability to navigate current demand shifts, some market participants remain cautious, debating whether the stock's recent price appreciation is already pricing in perfection.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is seeing a massive surge in investor activity driven by a $100 million strategic investment from Winklevoss Capital and a robust Q1 earnings report that exceeded revenue expectations. The community is heavily focused on the potential for a significant short squeeze due to high short interest and speculative hope that the company's new CFTC derivatives license will establish it as a key utility player in the crypto sector.

Robo.ai, Inc. engages in the design and development of smart electric vehicles. It aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology. The company was founded in 2016 and is headquartered in Dubai, United Arab Emirates.

Robo.ai Inc. - Ordinary Shares - Class B

Robo.ai Inc.

Robo.ai Inc. is experiencing extreme volatility driven by intense retail interest and a potential short squeeze, as community members focus on the company's emerging AI-integrated technology and rising borrow costs. Investors are debating whether to hold through significant price swings or lock in profits amid a backdrop of high social media chatter and momentum trading.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors react to news that the company has secured over 80% of Northern Data shares, signaling that the acquisition of critical AI and data center assets is nearing completion. The community is focused on this transformation into an AI-infrastructure play backed by Tether, with many discussing the potential for a significant short squeeze given the elevated short interest and upcoming earnings catalyst.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is experiencing significant volatility as investors react to a smaller-than-anticipated aircraft order from China, with the community divided between those interpreting the news as a sell-the-news event and others seeing a long-term accumulation opportunity. Market participants are actively debating whether this pullback is a temporary reaction to overly optimistic expectations or a deeper concern regarding the company's production stability and future order flow.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently surging to record highs, driven by reports that the U.S. government has approved the sale of advanced H200 AI chips to major Chinese tech firms. The community is actively discussing the stock's massive market capitalization and bullish momentum leading into next week's earnings, while weighing geopolitical risks against the company's sustained dominance in AI infrastructure.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors react to a significant earnings beat and raised full-year revenue guidance, sparking intense debate over whether the stock's growth potential justifies its complex capital structure. The community is actively weighing the company's surging backlog and defense partnerships against persistent concerns regarding dilution and the influence of market makers on share price volatility.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is facing significant volatility following its latest earnings report, as investors weigh the company's strong top-line revenue growth and customer acquisition against market concerns regarding margin compression and increased credit risk. The community remains deeply divided, with many long-term shareholders viewing the post-earnings dip as a prime accumulation opportunity for an expanding fintech powerhouse, while others express frustration over the stock's repeated pattern of selling off after reporting solid operational results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The agency’s top food official, Kyle Diamantas, will serve as acting commissioner following Makary’s exit.</li><li>Makary’s short but highly contentious tenure at the FDA was marked by frequent clashes with the pharmaceutical industry and some members of the Trump administration.</li><li>Makary is the latest top lieutenant to leave under Health and Human Services Secretary Robert F. Kennedy Jr.</li></ul>Shares of Replimune (REPL) and uniQure (QURE) jumped 7% and 5%, respectively, on Tuesday following reports that Marty Makary has resigned as commissioner of the Food and Drug Administration after weeks of mounting pressure from the Trump administration.The New York Times <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nytimes.com/2026/05/12/us/politics/trump-fires-fda-commissioner-makary.html?campaign_id&amp;#61;60&amp;emc&amp;#61;edit_na_20260512&amp;instance_id&amp;#61;175472&amp;nl&amp;#61;breaking-news&amp;regi_id&amp;#61;161176947&amp;segment_id&amp;#61;219731&amp;user_id&amp;#61;a73f770cbc17c7abf074a4b4265f078f">reported</a> that Makary’s departure was driven in large part by his strong opposition to the administration’s decision to authorize fruit-flavored e-cigarettes. Four people familiar with the matter told The Times that this clash played a central role in his resignation.President Donald Trump confirmed the report in a post on Truth Social. “I want to thank Dr. Marty Makary for having done a great job at the FDA. So much was accomplished under his leadership,” Trump said, while adding that the FDA’s top food official, Kyle Diamantas, will serve as acting commissioner. &nbsp;<h2 class="st-heading-2">Makary’s Tenure</h2>Makary’s short but highly contentious tenure at the FDA, the agency responsible for regulating drugs, vaccines, medical devices, tobacco products, and much of the nation’s food supply, was marked by frequent clashes with the pharmaceutical industry and some members of the Trump administration. Makary, a former Johns Hopkins surgeon, joined the FDA in November 2024.Makary is the <a href="https://stocktwits.com/news-articles/markets/equity/repl-qure-mrna-soar-on-reports-trump-will-fire-fda-marty-makary/cZX2uTvRegN">latest</a> top lieutenant to leave under Health and Human Services Secretary Robert F. Kennedy Jr., following the departures of CDC Director Susan Monarez last summer and HHS Deputy Secretary Jim O’Neill in February.The agency’s top food official, Kyle Diamantas, will serve as acting commissioner following Makary’s exit, The New York Times reported.<h2 class="st-heading-2">Why Are REPL And QURE Stocks Rallying?</h2>The FDA rejected Replimune’s lead melanoma therapy RP1 in a high-profile decision that drew intense industry backlash. Replimune argued the agency treated it unfairly and failed to honor prior commitments made during review meetings; the case became a flashpoint in broader criticism of Makary’s tenure.As for uniQure, the FDA issued a sudden “key shift” in feedback in March on the company’s Huntington’s disease gene therapy AMT-130, reversing earlier assurances about the sufficiency of its Phase 1/2 data. The FDA strongly recommended a new, randomized, double-blind, sham-surgery-controlled trial, to which the company expressed disagreement.While iShares US Pharmaceuticals ETF (<a href="https://stocktwits.com/symbol/IHE">IHE</a>) rose 1.3% at the time of writing, VanEck Pharmaceutical ETF (<a href="https://stocktwits.com/symbol/PPH">PPH</a>) was up nearly 2%.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL was within ‘bullish’ territory at the time of writing, while sentiment around QURE was ‘extremely bullish.’While <a href="https://stocktwits.com/symbol/REPL">REPL</a> fell 49% over the past 12 months, <a href="https://stocktwits.com/symbol/QURE">QURE</a> gained 120%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elvn-stock-climbs-as-guggenheim-launches-coverage-with-80-dollar-price-target-conference-data-unveil/cZXXmu1Reiw">ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. Food and Drug Administration (FDA) Commissioner Martin Makary arrives for a Senate Appropriations Committee hearing on Capitol Hill on May 22, 2025 in Washington, DC. (Photo by Anna Moneymaker/Getty Images)

REPL, QURE Stocks Rise Amid Makary’s Reported Resignation As FDA Chief

The New York Times reported that Makary’s departure was driven in large part by his strong opposition to the administration’s decision to authorize fruit-flavored e-cigarettes.

Equity

The New York Times reported that Makary’s departure was driven in large part by his strong opposition to the administration’s decision to authorize fruit-flavored e-cigarettes.


<ul class="summary-bullets"><li>The plans come on the heels of several complaints from the pharmaceutical industry and sparring with others in the health department over policy, the report added.</li><li>Makary, a former Johns Hopkins surgeon, joined the FDA in November 2024.</li><li>Shares of REPL and QURE jumped as much 17% following the report.</li></ul>President Donald Trump is reportedly considering firing U.S. Food and Drug Administration Commissioner Marty Makary.The Wall Street Journal <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/healthcare/trump-planning-to-fire-fda-commissioner-marty-makary-34c072e2">reported</a> on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency. The plans come on the heels of several complaints from the pharmaceutical industry and sparring with others in the health department over policy, the report added.However, the president’s plans are not final and could change, the report said. WSJ noted that Makary, if fired, would become the latest top lieutenant to be fired under Health and Human Services Secretary Robert F. Kennedy Jr., following the departures of CDC Director Susan Monarez last summer and HHS Deputy Secretary Jim O’Neill in February.Makary, a former Johns Hopkins surgeon, joined the FDA in November 2024.<h2 class="st-heading-2">Companies Likely To Benefit from Makary’s Exit</h2>Several biotech and pharmaceutical firms that have publicly clashed with the Makary-led FDA over what they describe as inconsistent, unpredictable, or overly restrictive drug-review processes are viewed as potential beneficiaries of new leadership that could accelerate approvals and restore clearer regulatory guidance.Replimune Group Inc. (<a href="https://stocktwits.com/symbol/REPL">REPL</a>): The FDA rejected the company’s lead melanoma therapy RP1 in a high-profile decision that drew intense industry backlash. Replimune argued the agency treated it unfairly and failed to honor prior commitments made during review meetings; the case became a flashpoint in broader criticism of Makary’s tenure.uniQure N.V. (<a href="https://stocktwits.com/symbol/QURE">QURE</a>): The agency issued a sudden “key shift” in feedback on the company’s Huntington’s disease gene therapy AMT-130, reversing earlier assurances about the sufficiency of its Phase 1/2 data. The FDA strongly recommended a new, randomized, double-blind, sham-surgery-controlled trial.Moderna Inc. (<a href="https://stocktwits.com/symbol/MRNA">MRNA</a>): CEO Stéphane Bancel publicly stated that the FDA under Makary had become “unpredictable” in a way that “threatens U.S. leadership in innovative medicines.” The company experienced surprise setbacks, including an initial refusal to accept a flu vaccine application that was later reversed.Regenxbio Inc. (<a href="https://stocktwits.com/symbol/RGNX">RGNX</a>): The FDA declined to approve the company’s gene therapy for the ultra-rare Hunter syndrome (MPS II) in February 2026, despite prior engagement. Industry observers cited this as part of a pattern of moving goalposts that has frustrated rare-disease developers.Sarepta Therapeutics Inc. (<a href="https://stocktwits.com/symbol/SRPT">SRPT</a>): Sarepta faced repeated conflicts over its Duchenne muscular dystrophy gene therapy Elevidys, including safety and efficacy disputes under Makary’s oversight and the influence of former FDA official Vinay Prasad.Other biotech stocks likely to benefit from under new FDA leadership include Hims &amp; Hers Health (<a href="https://stocktwits.com/symbol/HIMS">HIMS</a>), which faced direct public criticism from Makary over its compounded GLP-1 weight-loss products, and rare-disease gene- and RNA-therapy developers such as Dyne Therapeutics (<a href="https://stocktwits.com/symbol/DYN">DYN</a>), Avidity Biosciences (<a href="https://stocktwits.com/symbol/RNA">RNA</a>), and Lexeo Therapeutics (<a href="https://stocktwits.com/symbol/LXEO">LXEO</a>), all of which have cited inconsistent feedback and delays during Makary’s tenure.Shares of REPL jumped 17% at the time of writing, while QURE rose 15%. MRNA traded 10% higher, while SRPT stock traded 3% lower, and RGNX shares stayed flat.<h2 class="st-heading-2">How Did Retail Traders React?</h2>A Stocktwits user voiced optimism for eventual approval of Replimune’s RP-1 drug, calling the decision to deny it approval a “terrible one.”<stembedurl>https://www.stocktwits.com/History101/message/652782029</stembedurl>Another voiced optimism for “someone better” replacing Makary.<stembedurl>https://www.stocktwits.com/blueb22/message/652773597</stembedurl>While REPL shares fell by about 50% over the past 12 months, QURE rose 124%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lucid-uber-partnership-accelerates-after-nuro-lands-key-california-permit-for-gravity-robotaxis/cZX2AwwReg1">LCID-UBER Partnership Accelerates After Nuro Lands Key California Permit for Gravity Robotaxis</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

FDA Commissioner Marty Makary speaks at a news conference on removing synthetic dyes from America's food supply, at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. (Photo by Nathan Posner/Anadolu via Getty Images)

REPL, QURE, MRNA Soar On Reports Trump Will Fire FDA’s Marty Makary 

The Wall Street Journal reported on the plans on Friday, citing people familiar with the matter, while noting that other top administration officials believe Makary is struggling to manage his agency.

uniQure Q1 Earnings Call Highlights

uniQure (NASDAQ:QURE) executives outlined progress and upcoming regulatory milestones for lead Huntington's disease gene therapy candidate AMT-130 during the company's first-quarter 2026 earnings call, while also providing updates across its epilepsy and Fabry programs and reviewing quarterly financ...

uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results

uniQure (NASDAQ:QURE - Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts...

uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +2.86% and -48.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

uniQure (NASDAQ:QURE) Shares Up 6.3% - Still a Buy?

uniQure (NASDAQ:QURE) Stock Price Up 6.3% - Time to Buy...

Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE

Jennison Associates LLC raised its position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 37.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,371,190 shares of the biotechnology company's s...

uniQure (QURE) Projected to Post Earnings on Tuesday

uniQure (NASDAQ:QURE) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-uniqure-stock...

uniQure (NASDAQ:QURE) Given New $37.00 Price Target at Chardan Capital

Chardan Capital raised their price objective on uniQure from $31.00 to $37.00 and gave the stock a "buy" rating in a research report on Thursday...

uniQure (NASDAQ:QURE) Shares Gap Up   - Here's Why

uniQure (NASDAQ:QURE) Shares Gap Up - What's Next...

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

QURE
uniQure NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QURE News

QUREuniQure NV